| [1] |
Wang CX, Pusic I, Anadkat MJ. Association of leukemia cutis with survival in acute myeloid leukemia[J]. JAMA Dermatol, 2019, 155(7): 826-832. DOI: 10.1001/jamadermatol.2019.0052.
pmid: 30969325
|
| [2] |
Martínez-Leboráns L, Victoria-Martínez AM, Torregrosa-Calatayud JL, et al. Leukemia cutis: a report of 17 cases and a review of the literature[J]. Actas Dermosifiliogr, 2016, 107(9): e65-e69. DOI: 10.1016/j.ad.2016.02.015.
|
| [3] |
Sandre M, Osmond A, Ghazarian D, et al. Bullous leukemia cutis: a rare clinical subtype[J]. Dermatol Online J, 2019, 25(6): 13030. DOI: 10.5070/D3256044494.
|
| [4] |
Aldapt MB, Yassin M. Leukemia cutis as an early presentation or relapsing manifestation of chronic lymphocytic leukemia (CLL)[J]. Acta Biomed, 2021, 92(2): e2021192. DOI: 10.23750/abm.v92i2. 10763.
|
| [5] |
Agis H, Weltermann A, Fonatsch C, et al. A comparative study on demographic, hematological, and cytogenetic findings and prognosis in acute myeloid leukemia with and without leukemia cutis[J]. Ann Hematol, 2002, 81(2): 90-95. DOI: 10.1007/s00277-001-0412-9.
pmid: 11907789
|
| [6] |
Robak E, Braun M, Robak T. Leukemia cutis-the current view on pathogenesis, diagnosis, and treatment[J]. Cancers (Basel), 2023, 15(22): 5393. DOI: 10.3390/cancers15225393.
|
| [7] |
Cho-Vega JH, Medeiros LJ, Prieto VG, et al. Leukemia cutis[J]. Am J Clin Pathol, 2008, 129(1): 130-142. DOI: 10.1309/WYACYWF6NGM3WBRT.
pmid: 18089498
|
| [8] |
Bystrom R, Levis MJ. An update on FLT3 in acute myeloid leukemia: pathophysiology and therapeutic landscape[J]. Curr Oncol Rep, 2023, 25(4): 369-378. DOI: 10.1007/s11912-023-01389-2.
|
| [9] |
Wang ES, Goldberg AD, Tallman M, et al. Crenolanib and intensive chemotherapy in adults with newly diagnosed FLT3-mutated AML[J]. J Clin Oncol, 2024, 42(15): 1776-1787. DOI: 10.1200/JCO.23. 01061.
|
| [10] |
Daver N, Schlenk RF, Russell NH, et al. Targeting FLT3 mutations in AML: review of current knowledge and evidence[J]. Leukemia, 2019, 33(2): 299-312. DOI: 10.1038/s41375-018-0357-9.
pmid: 30651634
|
| [11] |
Antar AI, Otrock ZK, Jabbour E, et al. FLT3 inhibitors in acute myeloid leukemia: ten frequently asked questions[J]. Leukemia, 2020, 34(3): 682-696. DOI: 10.1038/s41375-019-0694-3.
pmid: 31919472
|
| [12] |
Grafone T, Palmisano M, Nicci C, et al. An overview on the role of FLT3-tyrosine kinase receptor in acute myeloid leukemia: biology and treatment[J]. Oncol Rev, 2012, 6(1): e8. DOI: 10.4081/oncol.2012.e8.
|
| [13] |
陈曦, 母丹, 严钦, 等. 骨髓微环境与白血病细胞分化[J]. 国际肿瘤学杂志, 2021, 48(3): 189-192. DOI: 10.3760/cma.j.cn371439- 20200619-00038.
|
| [14] |
Song MK, Park BB, Uhm JE. Clinical efficacies of FLT3 inhibitors in patients with acute myeloid leukemia[J]. Int J Mol Sci, 2022, 23(20): 12708. DOI: 10.3390/ijms232012708.
|
| [15] |
Karagounis TK, Rotemberg V, Geskin LJ, et al. NPM1 and FLT3-TKD mutations are enriched in patients with leukemia cutis[J]. Dermatol Online J, 2020, 26(7): 13030/qt5gc4c36x. DOI: 10. 5070/D3267049552.
|
| [16] |
Ansari-Lari MA, Yang CF, Tinawi-Aljundi R, et al. FLT3 mutations in myeloid sarcoma[J]. Br J Haematol, 2004, 126(6): 785-791. DOI: 10.1111/j.1365-2141.2004.05124.x.
|
